HONG KONG: Hong Kong authorities on Wednesday halted the use of a COVID-19 vaccine developed by Pfizer and BioNTech citing defective packaging, triggering scenes of confusion in inoculation centres across the city.
The suspension comes as the Asian financial hub has faced a sluggish take-up of vaccines due to dwindling confidence in China's Sinovac Biotech Ltd treatment and fears of adverse reactions.
Inoculation centre staff turned away residents booked to take the Pfizer/BioNTech vaccine, with many Hong Kong-ers unsure as to the reason and asking for explanations. Adding to the confusion, local media reports said one doctor was reprimanded for promoting the Pfizer/BioNTech vaccine over Sinovac's.
"As a precautionary measure BioNTech requested the suspension" for its vaccines in Hong Kong until an investigation is complete, the city's Director of Health, Dr Constance Chan, told a news conference on Wednesday afternoon.
The city started vaccinating residents with doses from Sinovac in February and began offering the one developed by Pfizer and its partner, BioNTech, in March.
The Pfizer/BioNTech vaccine has shown greater take-up since its launch with the number of residents booking that shot more than double those booking Sinovac over the past week, according to government figures. Chan said the government had initially contacted Fosun Industrial (Hong Kong), the distributor of the Pfizer/BioNTech vaccine in Hong Kong and Macau, after it found some cases of cracks in vaccine containers and stains on some bottles.
She said Fosun replied on Wednesday morning stating that it needed to further investigate and would suspend vaccination until further notice.
"BioNTech and Fosun have not found any reason to believe that product safety is at risk," she said.
Fosun's parent company, Shanghai Fosun Pharmaceutical, said in a filing on Wednesday it was investigating with BioNTech.
Macau said on Wednesday it was also suspending the Pfizer/BioNTech vaccine due to the packaging flaw.
Officials said Sinovac vaccinations would continue to take place as scheduled.
WAIT AND SEE
In a separate incident, Hong Kong's government said it shut a private clinic that administered COVID-19 vaccines after a doctor surnamed Lau "violated an agreement" under the city's inoculation programme.
Broadcaster RTHK reported that Lau recommended people take the Pfizer/BioNTech shot rather than the Sinovac one due to a better international reputation for the former.
Lau did not immediately respond to requests for comment. His clinic had been providing Sinovac vaccines and not the Pfizer/BioNTech ones, which are only available at larger public sector facilities. Distrust of the mainland has intensified among residents in recent years with months of anti-government and anti-China protests driven by a perception that Beijing is pushing the semi-autonomous city onto a more authoritarian path.
Media reports of several deaths after vaccinations have also kept some people jittery even though the government has said there was no direct link between the shots and the deaths.
With low levels of infection in the city, many people are opting to wait and see before getting a shot.
"I won't get vaccinated yet, I'm going to wait until more people get it," said one 40-year-old man who gave his name as Leung.
"I have more confidence in BioNTech. It's a foreign one after all ... the quality is guaranteed." Only about 5% of Hong Kong's 7.5 million residents have been vaccinated, and more than one third of them received the Pfizer/BioNTech shot.
For one 67-year-old resident, who gave his surname as Lau, there was no question as to which vaccine he was going for on Tuesday - the Pfizer/BioNTech one.
"It has better data, there are more people getting it internationally," he said. "The other one, the data is not clear."
City leader Carrie Lam has repeated called for people to get vaccinated.
"When many places all over the world are scrambling for vaccines, we have a pretty assured supply," she said on Tuesday.
Reuters
Wed Mar 24 2021
People leave a vaccination centre after Hong Kong temporarily suspended COVID-19 vaccine from a single batch of Pfizer/BioNTech shots due to packaging defects, in Hong Kong, China March 24, 2021. REUTERSpic
Who is Prabowo Subianto, incoming president of Indonesia?
A wealthy ex-general with ties to Indonesia's popular outgoing president and its dictatorial past, looks set to be its next leader.
Iran's supreme leader says Hamas leader's death will not halt 'Axis of Resistance'
The "Axis of Resistance", built up with years of Iranian support, includes Hamas, the Lebanese Hezbollah group, the Houthi movement in Yemen, and various Shi'ite groups in Iraq and Syria.
Putin says Russia willing to seek compromises between Iran and Israel
Russia is ready to help seek compromises between arch-foes Israel and Iran, President Vladimir Putin said on Friday, saying these would be difficult but possible.
What proposals will Russia push at the BRICS summit?
The proposal is also to establish a BRICS reinsurance company to allow uninterrupted shipment of goods and key commodities between members.
Indonesia's free meals plan in the spotlight as Prabowo readies for office
Prabowo calls the programme one of the main drivers of economic growth, eventually set to add an estimated 2.5 million jobs.
Astro AWANI's revamped English news website, AWANI International, launches on Oct 21
Astro AWANI's revamped English platform delivers in-depth global news and expert analysis to keep you informed on key developments.
Israeli strikes kill 33 people in Jabalia refugee camp in Gaza, medics say
Residents of Jabalia said Israeli tanks had reached the heart of the camp after pushing through suburbs and residential districts.
Liam Payne's ex-partner calls for media restraint after 'painful' death
Cheryl Tweedy used her statement to urge the media to remember they had a seven-year-old son, Bear, who could read the reports.
Analysts: Indonesia's strong MoF leadership team to boost investor confidence
Sri Mulyani Indrawati as head of Indonesia's Ministry of Finance is expected to instil confidence among investors.
Biden offers both a carrot and a stick to Israel as his term nears an end
Israel has frequently resisted US advice and has caused political difficulties for the Biden administration.
Putin says BRICS will generate most of global economic growth
Russian President Vladimir Putin will host a summit of the group in the city of Kazan on Oct. 22-24.
ISIS Malaysia's perspective of Budget 2025
An excellent rakyat-centric budget under the overarching principle of a caring and humane economy.
Budget 2025: Record increase in STR, SARA aid initiatives
The government will provide a significant boost to the Sumbangan Tunai Rahmah (STR) and Sumbangan Asas Rahmah (SARA) initiatives next year.
Budget 2025: EPF contributions to be made mandatory for foreign workers – PM Anwar
The government plans to make it compulsory for all non-citizen workers to contribute to the Employees Provident Fund (EPF).
What policies to expect from Indonesia's new President Prabowo
Prabowo will be open to foreign investment, his aide has said, such as by offering investors management of airports and sea ports.
Budget 2025: Govt allocates RM470 mil to empower women's participation in PMKS
The Women's Leadership Apprenticeship Program will be intensified as an effort to produce more female corporate personalities.
Israel sends more troops into north Gaza, deepens raid
Residents of Jabalia in northern Gaza said Israeli tanks had reached the heart of the camp, using heavy air and ground fire.
Indonesia ramps up security ahead of Prabowo's inauguration
Prabowo Subianto will be sworn in as Indonesia's president on Sunday with Vice President-elect, Gibran Rakabuming Raka, also taking office.
Immediate allocation of RM150 mil for local authorities, DID to tackle flash floods
Datuk Seri Anwar Ibrahim said this allocation is intended to address the recent flash floods that hit the capital and several major towns.
Budget 2025: Sabah, Sarawak to continue receiving among highest allocations - PM
Sabah and Sarawak continues to be prioritised under Budget 2025, with allocations of RM6.7 billion and RM5.9 billion respectively.